ISItender Singh

Itender Singh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Itender Singh has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The caspase 11/gasdermin D pathway is a key driver of stress-induced neuroinflammation and behavioral dysfunction in rats

    by Soni Tiwari, Zaidan Mohammed, Aryan Tiwari, Ekta Yadav, Santi Ranjan Atta, Shweta Kaushik, Amla Chopra, Itender Singh, Simantini Ghosh

  • Open Access

    TRIM21 drives stress-induced neuroinflammation and behavioral deficits via gasdermin D- dependent IL-1β release in a rat model of repeated social defeat

    by Soni Tiwari, Zaidan Mohammed, Santi Ranjan Atta, Aryan Tiwari, Ekta Yadav, Shweta Kaushik, Amla Chopra, Itender Singh, Simantini Ghosh

    The upstream mechanism that transduces psychosocial stress into the release of the pivotal pro-inflammatory cytokine IL-1β has remained a fundamental gap in understanding neuropsychiatric disorders. Here, we identify tripartite motif-containing protein 21 (TRIM21) as the critical trigger. In a rat model of repeated social defeat, TRIM21 was upregulated in the hippocampus, brain microvessels, and peripheral blood mononuclear cells (PBMCs), correlating with anxiety-like behavior and memory deficits, with females exhibiting a more pronounced pathophysiology. Mechanistically, TRIM21 directly binds to and promotes the cleavage of gasdermin D, facilitating the formation of membrane pores for IL-1β release. This pathway was active in PBMCs, where TRIM21 drove sub-lytic pore formation and IL-1β release, linking peripheral inflammation to behavioral deficits. Critically, in vivo TRIM21 knockdown abrogated this pathway systemically, reducing IL-1β release and NF-κB signaling, which in turn rescued blood-brain barrier integrity, restored synaptic density, and normalized behavior. Using an in vitro blood-brain barrier model, we pinpointed this effect to a TRIM21-IL-1β-p65 axis. We therefore define TRIM21 as the critical node in a stress-responsive circuit, bridging peripheral immune activation to GSDMD-dependent neuroinflammation and blood-brain barrier disruption, thereby providing a mechanistic framework that redefines the pathophysiology of stress-related neuropsychiatric disorders and reveals new avenues for their treatment.

  • Open Access

    STAT3 inhibitor mitigates cerebral amyloid angiopathy and parenchymal amyloid plaques while improving cognitive functions and brain networks

    by Jogender Mehla, Itender Singh, Deepti Diwan, James W. Nelson, Molly Lawrence, Eunjae Lee, Adam Q. Bauer, David M. Holtzman, Gregory J. Zipfel

    Previous reports indicate a potential role for signal transducer and activator of transcription 3 (STAT3) in amyloid-β (Aβ) processing and neuritic plaque pathogenesis. In the present study, the impact of STAT3 inhibition on cognition, cerebrovascular function, amyloid pathology, oxidative stress, and neuroinflammation was studied using in vitro and in vivo models of Alzheimer’s disease (AD)-related pathology. For in vitro experiments, human brain vascular smooth muscle cells (HBVSMC) and human brain microvascular endothelial cells (HBMEC) were used, and these cultured cells were exposed to Aβ peptides followed by measurement of activated forms of STAT3 expression and reactive oxygen species (ROS) generation. Further, 6 months old 5XFAD/APOE4 (5XE4) mice and age-matched negative littermates were used for in vivo experiments. These mice were treated with STAT3 specific inhibitor, LLL-12 for 2 months followed by neurobehavioral and histopathological assessment. In vitro experiments showed exposure of cerebrovascular cells to Aβ peptides upregulated activated forms of STAT3 and produced STAT3-mediated vascular oxidative stress. 5XE4 mice treated with the STAT3-specific inhibitor (LLL-12) improved cognitive functions and functional connectivity and augmented cerebral blood flow. These functional improvements were associated with a reduction in neuritic plaques, cerebral amyloid angiopathy (CAA), oxidative stress, and neuroinflammation. Reduction in amyloid precursor protein (APP) processing and attenuation of oxidative modification of lipoprotein receptor related protein-1 (LRP-1) were identified as potential underlying mechanisms. These results demonstrate the broad impact of STAT3 on cognitive functions, parenchymal and vascular amyloid pathology and highlight the therapeutic potential of STAT3 specific inhibition for treatment of AD and CAA.